ATE251458T1 - Nervenschutzende für auge von säugern unter anwendung von kaliumkanalblockern - Google Patents

Nervenschutzende für auge von säugern unter anwendung von kaliumkanalblockern

Info

Publication number: ATE251458T1
Authority: AT; Austria
Prior art keywords: potassium channel; channel blockers; protectives; nerve; mammal eyes
Prior art date: 1995-04-28

Application number

AT02009867T

Other languages

English (en)

Inventor

Joseph S Adorante

Elizabeth Woldemussie

Guadalupe Ruiz

Original Assignee

Allergan Sales Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-28

Filing date

1996-04-16

Publication date

2003-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23710776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE251458(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-16 Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE251458T1 publication Critical patent/ATE251458T1/de

Links

239000003450 potassium channel blocker Substances 0.000 title abstract 2
241000124008 Mammalia Species 0.000 title 1
210000005036 nerve Anatomy 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 3
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
108010023798 Charybdotoxin Proteins 0.000 abstract 1
235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
241000238631 Hexapoda Species 0.000 abstract 1
206010030043 Ocular hypertension Diseases 0.000 abstract 1
HSFKQYJRJBEWKH-XTHGXZEWSA-N Paspalicine Chemical compound C1=CC=C2C(C[C@@H]3CC[C@@H]4[C@]([C@@]53C)(C)CC[C@]36OC([C@H](C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-XTHGXZEWSA-N 0.000 abstract 1
HSFKQYJRJBEWKH-UHFFFAOYSA-N Paspalicine Natural products C1=CC=C2C(CC3CCC4C(C53C)(C)CCC36OC(C(C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-UHFFFAOYSA-N 0.000 abstract 1
JDUWHZOLEDOQSR-JKPSMKLGSA-N Penitrem A Chemical compound O([C@H]1[C@H]2[C@@](C(N3)=C11)(C)[C@@]4(C)CC[C@@H]5O[C@@H]([C@@H]([C@H]6O[C@@]56[C@]4(O)CC2)O)C(=C)C)C(C)(C)[C@H]2C[C@H]4[C@]2(O)C2=C1C3=CC(Cl)=C2CC4=C JDUWHZOLEDOQSR-JKPSMKLGSA-N 0.000 abstract 1
102000004257 Potassium Channel Human genes 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 abstract 1
VDNVVLOBNHIMQA-UHFFFAOYSA-N iberiotoxin Chemical compound C1SSCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C1NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC1=O)CSSCC1NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)NC1=O)CSSCC1NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 VDNVVLOBNHIMQA-UHFFFAOYSA-N 0.000 abstract 1
108010068927 iberiotoxin Proteins 0.000 abstract 1
229930005303 indole alkaloid Natural products 0.000 abstract 1
150000002475 indoles Chemical class 0.000 abstract 1
JDUWHZOLEDOQSR-UHFFFAOYSA-N penitrem A Natural products C1CC2(O)C34OC4C(O)C(C(=C)C)OC3CCC2(C)C(C(N2)=C34)(C)C1C3OC(C)(C)C1CC3C1(O)C1=C4C2=CC(Cl)=C1CC3=C JDUWHZOLEDOQSR-UHFFFAOYSA-N 0.000 abstract 1
108020001213 potassium channel Proteins 0.000 abstract 1
229960000948 quinine Drugs 0.000 abstract 1
239000003053 toxin Substances 0.000 abstract 1
231100000765 toxin Toxicity 0.000 abstract 1
108700012359 toxins Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Eye Examination Apparatus (AREA)
Medicinal Preparation (AREA)

AT02009867T 1995-04-28 1996-04-16 Nervenschutzende für auge von säugern unter anwendung von kaliumkanalblockern ATE251458T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/431,170 US5573758A (en)	1995-04-28	1995-04-28	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Publications (1)

Publication Number	Publication Date
ATE251458T1 true ATE251458T1 (de)	2003-10-15

Family

ID=23710776

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02009867T ATE251458T1 (de)	1995-04-28	1996-04-16	Nervenschutzende für auge von säugern unter anwendung von kaliumkanalblockern
AT96912798T ATE225658T1 (de)	1995-04-28	1996-04-16	Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT96912798T ATE225658T1 (de)	1995-04-28	1996-04-16	Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker

Country Status (8)

Country	Link
US (1)	US5573758A (de)
EP (2)	EP0825863B1 (de)
JP (2)	JPH11504330A (de)
AT (2)	ATE251458T1 (de)
AU (1)	AU703241B2 (de)
DE (2)	DE69624234D1 (de)
ES (2)	ES2204879T5 (de)
WO (1)	WO1996033719A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69634414T2 (de)	1995-12-21	2005-11-17	Alcon Laboratories, Inc., Fort Worth	Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US5925342A (en) *	1996-11-13	1999-07-20	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP1251862B1 (de) *	2000-01-18	2008-10-01	Merck & Co., Inc.	Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
US6548535B2 (en) *	2000-01-18	2003-04-15	Merck & Co., Inc.	Method for treating ocular hypertension
AU2002240051B2 (en) *	2001-01-30	2006-06-01	Merck & Co., Inc.	Method for identifying maxi-K channel blockers
CA2434485A1 (en) *	2001-01-30	2002-08-08	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
US20040115739A1 (en) *	2002-01-25	2004-06-17	Garcia Maria L	Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells
US7119112B2 (en) *	2002-02-28	2006-10-10	Icagen, Inc.	Sulfonamides as potassium channel blockers
AU2003217810C9 (en) *	2002-02-28	2008-06-12	Icagen, Inc.	Methods for treating diseases related to intraocular pressure
EP1487438A4 (de) *	2002-03-15	2007-08-15	Merck & Co Inc	Zusammensetzungen und verfahren zur behandlung von glaukom und okularer hypertonie
CA2488802A1 (en) *	2002-06-14	2003-12-24	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
JP2005533055A (ja) *	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	新規マキシｋチャンネルブロッカー、その使用方法および製造方法
CA2488884A1 (en) *	2002-06-17	2003-12-24	Merck & Co., Inc.	Novel maxi-k channel blockers, methods of use and process for making the same
WO2004043354A2 (en) *	2002-11-08	2004-05-27	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) *	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
CA2519899A1 (en)	2003-03-27	2004-10-14	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
CN1816530A (zh) *	2003-07-01	2006-08-09	麦克公司	用于治疗高眼压症的眼用组合物
CN1845914A (zh) *	2003-09-02	2006-10-11	默克公司	用于治疗眼压过高的眼用组合物
AU2004271978B2 (en) *	2003-09-04	2009-02-05	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en) *	2003-09-04	2007-10-18	Merck Sharp & Dohme Corp.	Ophthalmic compositions for treating ocular hypertension
US20050250779A1 (en) *	2004-05-04	2005-11-10	Song Zhu	Pteridinone derivatives for treating ocular hypertension
CN1988903A (zh)	2004-07-20	2007-06-27	默克公司	用于治疗高眼压症的眼用组合物
US20080097108A1 (en) *	2004-10-13	2008-04-24	Ying-Duo Gao	Ophthalmic Compositions for Treating Ocular Hypertension
US20070293558A1 (en) *	2004-10-13	2007-12-20	Ying-Duo Gao	Ophthalmic Compositions for Treating Ocular Hypertension
CA2644716A1 (en) *	2006-03-13	2007-09-27	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
AU2007258527A1 (en) *	2006-06-12	2007-12-21	Merck Sharp & Dohme Corp.	Ophthalmic compositions for treating ocular hypertension
EP1941876A1 (de) *	2006-12-28	2008-07-09	Lacer, S.A.	Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
EP2436387B1 (de) *	2009-05-25	2018-07-25	Celgene Corporation	Pharmazeutische zusammensetzung enthaltend crbn zur verwendung in der behandlung von krankeiten des cerebralen cortex.
EP3096142A3 (de)	2011-04-29	2017-03-08	Celgene Corporation	Verfahren zur behandlung von krebs oder entzündungserkrankungen mit cereblon als prädiktor
CA2877736C (en)	2012-06-29	2021-12-07	Celgene Corporation	Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP3160486B1 (de)	2014-06-27	2020-11-18	Celgene Corporation	Zusammensetzungen und verfahren zur induktion von konformationsänderungen bei cereblon und anderen e3-ubiquitin-ligasen
US10830762B2 (en)	2015-12-28	2020-11-10	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3693789A (en) *	1988-05-10	1989-11-29	Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab)	New ophthalmic preparation for treating glaucoma
EP0430621A3 (en) *	1989-11-29	1992-03-04	Beecham Group P.L.C.	Process for the preparation of chiral 3,4-epoxy benzopyrans
US5512591A (en) *	1993-02-18	1996-04-30	President And Fellows Of Harvard College	Treatments for diseases characterized by neovascularization
CA2164733A1 (en) *	1993-06-08	1994-12-22	Nino Sorgente	Methods and compositions for lowering intraocular pressure
US5494895A (en) *	1993-07-22	1996-02-27	Merck & Co., Inc.	Scorpion peptide margatoxin with immunosuppressant activity
GB9316111D0 (en) *	1993-08-04	1993-09-22	Pfizer Ltd	Benzopyrans

1995
- 1995-04-28 US US08/431,170 patent/US5573758A/en not_active Expired - Lifetime
1996
- 1996-04-16 EP EP96912798A patent/EP0825863B1/de not_active Expired - Lifetime
- 1996-04-16 AU AU55488/96A patent/AU703241B2/en not_active Ceased
- 1996-04-16 AT AT02009867T patent/ATE251458T1/de not_active IP Right Cessation
- 1996-04-16 ES ES02009867T patent/ES2204879T5/es not_active Expired - Lifetime
- 1996-04-16 AT AT96912798T patent/ATE225658T1/de not_active IP Right Cessation
- 1996-04-16 DE DE69624234T patent/DE69624234D1/de not_active Expired - Lifetime
- 1996-04-16 EP EP02009867A patent/EP1243270B2/de not_active Expired - Lifetime
- 1996-04-16 ES ES96912798T patent/ES2182973T3/es not_active Expired - Lifetime
- 1996-04-16 JP JP8532585A patent/JPH11504330A/ja not_active Withdrawn
- 1996-04-16 WO PCT/US1996/005241 patent/WO1996033719A1/en not_active Ceased
- 1996-04-16 DE DE69630325T patent/DE69630325T3/de not_active Expired - Lifetime
2007
- 2007-06-06 JP JP2007150243A patent/JP2007217437A/ja active Pending

Also Published As

Publication number	Publication date
US5573758A (en)	1996-11-12
ES2204879T5 (es)	2009-06-19
JP2007217437A (ja)	2007-08-30
ES2182973T3 (es)	2003-03-16
DE69630325T2 (de)	2004-07-29
EP1243270B1 (de)	2003-10-08
AU703241B2 (en)	1999-03-25
AU5548896A (en)	1996-11-18
EP1243270A1 (de)	2002-09-25
DE69630325D1 (de)	2003-11-13
ES2204879T3 (es)	2004-05-01
ATE225658T1 (de)	2002-10-15
EP1243270B2 (de)	2009-03-25
WO1996033719A1 (en)	1996-10-31
EP0825863A1 (de)	1998-03-04
DE69624234D1 (de)	2002-11-14
JPH11504330A (ja)	1999-04-20
DE69630325T3 (de)	2009-11-19
EP0825863B1 (de)	2002-10-09

Legal Events

Date	Code	Title	Description
2004-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69630325D1 (de)	2003-11-13	Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern
BR9611748A (pt)	1999-06-01	Uso de um produto protéico de fator neurotrófico derivado de linhagem de célula glial
ES2062102T3 (es)	1994-12-16	Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
ATE480240T1 (de)	2010-09-15	Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
ATE273009T1 (de)	2004-08-15	Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
ATE162074T1 (de)	1998-01-15	Oculare hypotensive mittel
EP1110554A4 (de)	2002-02-06	Medizinische zusammensetzungen zur behandlung von augenerkrankungen
NO884020L (no)	1989-03-13	Konserveringsmiddelsystem for ofthalmiske preparater.
DE69521620D1 (de)	2001-08-09	Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
BR0210241A (pt)	2004-08-10	Piranoindazóis e seu uso no tratamento de glaucoma
ATE289815T1 (de)	2005-03-15	Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
DE69320405D1 (de)	1998-09-24	Ophthalmische Zusammensetzungen enthaltend als Wirkstoff Vitamin-E oder Ester davon
ES2131373T3 (es)	1999-07-16	Composicion oftalmica para prevenir o tratar el ojo seco o una enfermedad causada por el mismo, que comprende acido 12-sulfodeshidroabietico.
BR9914128A (pt)	2002-09-24	Composições antibióticas para tratamento do olho, ouvido e nariz
BR9107071A (pt)	1993-09-21	2-decarboxil-2-aminoalquil-prostag landinas como hipotensivos oculares
BR0316040A (pt)	2005-09-13	Composto, métodos para tratar doenças, para tratar edema macular, degeneração macular, aumentar a velocidade do sangue retinal e da cabeça do nervo óptico, aumentar a tensão de oxigênio retinal e do nervo óptico e/ou um efeito neuroprotetor, para prevenir a repolarização ou a hiperpolarização de uma célula de mamìfero contendo canal de potássio, e para tratar do diabete, e, composição
ATE233554T1 (de)	2003-03-15	Produkte zur behandlung von glaukoma
ATE109136T1 (de)	1994-08-15	Substituierte cyclohexene mit zentraler nervensystem-wirkung.
BR9302024A (pt)	1993-11-30	Composicao cosmetica apropriada para aplicacao topica na pele ou cabelo de mamiferos e processos para a producao da mesma e para tratamento cosmetico
ATE359774T1 (de)	2007-05-15	Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
EP1410808A4 (de)	2009-07-29	Mittel zum schutz des sehnervs mit alpha-1-rezeptor-blocker als wirkstoff
DE69829062D1 (de)	2005-03-24	Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
CA2219280A1 (en)	1996-10-31	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
BR0109192A (pt)	2003-05-27	Tratamento de hipertensão ocular e glaucoma.
DE69829227D1 (de)	2005-04-07	Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom